Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.

Aims: Modifications of antimicrobials' pharmacokinetic parameters have been reported in critically ill patients, resulting in a risk of treatment failure. We characterized amikacin pharmacokinetic variability in critically ill patients with ventilator-associated pneumonia (VAP) and evaluated several...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 71; no. 1; pp. 75 - 84
Autores principales: Burdet, C., Pajot, O., Couffignal, C., Armand-Lefèvre, L., Foucrier, A., Laouénan, C., Wolff, M., Massias, L., Mentré, F.
Formato: research tables/charts Journal Article
Publicado: Springer Nature Jan2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103866208&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 103866208
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Jan2015
      vid: 71
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        103866208
        100209207
        10.1007/s00228-014-1766-y
        103866208
      ppf: 75
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
      aug:
        au:
          Burdet, C.
          Pajot, O.
          Couffignal, C.
          Armand-Lefèvre, L.
          Foucrier, A.
          Laouénan, C.
          Wolff, M.
          Massias, L.
          Mentré, F.
        affil: V. Dupouy Hospital, Intensive Care Unit 95107 Argenteuil France
      sug:
        subj:
          Amikacin Administration and Dosage
          Amikacin Pharmacokinetics
          Pneumonia, Ventilator-Associated Drug Therapy
          Pneumonia, Ventilator-Associated Diagnosis
          Critically Ill Patients
          Human
          Prospective Studies
          Multicenter Studies
          Imipenem Administration and Dosage
          Descriptive Statistics
          Male
          Female
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          France
          Algorithms
          Simulations
          Clinical Assessment Tools
          Confidence Intervals
          Funding Source
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Aims: Modifications of antimicrobials' pharmacokinetic parameters have been reported in critically ill patients, resulting in a risk of treatment failure. We characterized amikacin pharmacokinetic variability in critically ill patients with ventilator-associated pneumonia (VAP) and evaluated several dosing regimens. Methods: We conducted a prospective multicenter study in critically ill patients with presumptive diagnosis of Gram-negative bacilli (GNB) VAP. Patients empirically received imipenem and a single-dose of amikacin, which was administered as a 30-min infusion (20 mg/kg). Concentrations were measured 0.5, 1, 8, 16, and 24 h after beginning of infusion. Pharmacokinetic parameters were estimated using a population approach. Main pharmacodynamic target was a ratio ≥10 between the concentration achieved 1 h after beginning of infusion ( C) and the minimal inhibitory concentration of the liable bacteria (MIC). We simulated individual C for several dosing regimens by Monte Carlo method and computed C/MIC ratios for MICs from 0.5 to 64 mg/L. Results: Sixty patients (47 males), median (range) age, and body weight, 61.5 years (28-84) and 78 kg (45-126), respectively, were included. Amikacin median C was 45 mg/L (22-87). Mean value (between-patients variability) for CL, V1, Q, and V2 were 4.3 L/h (31 %), 15.9 L (22 %), 12.1 L/h (27 %), and 21.4 L (47 %), respectively. CL increased with CrCL ( p < 0.001) and V1 with body weight ( p < 0.001) and PaO/FIO ratio ( p < 0.001). With a 25 mg/kg regimen, the pharmacodynamic target was achieved in 20 and 96 % for a MICs of 8 and 4 mg/L, respectively. Conclusion: Amikacin clearance was decreased and its volume of distribution was increased as previously reported. A ≥25 mg/kg single-dose is needed for empirical treatment of GNB-VAP.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N